Regeneron falls
Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
This was the stock's third consecutive day of losses.
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.
The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...
Shares of Regeneron Pharmaceuticals Inc. REGN slid 3.58% to $718.16 Tuesday, on what proved to be an all-around grim trading ...
Pictured from left, Commack Superintendent Jordan Cox, Research Coordinator Jeanette Collette, Legislator Rob Trotta, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback